Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease

Fig. 4

Change in CSF biomarkers from baseline at 24 weeks. CSF was collected at baseline and 24 weeks and analyzed for biomarkers associated with AD including Aβ40 (A), Aβ42 (B), Tau (C), pTau (D), neurogranin (E), synaptotagmin (F), SNAP-25 (G), and NfL (H). The mean changes from baseline (error bars: SE) are shown. No significant differences were demonstrated between any treatment groups in the change from baseline at 24 weeks

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193